Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




Medivation Lags Expectations – Analyst Blog

Zacks Market Commentaries (November 6th, 2009) Writes:
Medivation Inc. (MDVN) has reported a net loss of 42 cents per share in the third quarter of 2009, exceeding the Zacks Consensus Estimate of a net loss of 39 cents. However, net loss declined from the year-ago loss of 68 cents.  Revenue for the quarter was $16.3 million, consisting of partial recognition of the non-refundable upfront payment of $225 million received from Pfizer (PFE) in October 2008. The upfront payment is being recognized on a straight-line basis through the first quarter of 2012. Revenues were nil in the year-ago period.  Operating expenses grew from $20.6 million in the year-ago period to $27.6 million in the quarter. Research and development expenses increased to $21.5 million as a result of greater clinical trials expenses which were partially offset by a cost share reimbursement under the company’s agreement with Pfizer. With Dimebon and MDV3100 moving into advanced ...

MannKind Beats, Awaiting FDA – Analyst Blog

Zacks Market Commentaries (November 3rd, 2009) Writes:
MannKind Pharma’s (MNKD) third quarter loss per share came in at 42 cents, better than the Zacks Consensus Estimate of 49 cents and loss of 67 cents reported in the year-ago period. The company does not have any revenue stream at present -- its lead product, Afresa (inhaled insulin for the treatment of type I and type II diabetes) is currently under US Food and Drug Administration (FDA) review. MannKind filed a New Drug Application (NDA) for Afresa with the FDA in March 2009, which was subsequently accepted in May 2009. The company has been assigned a Prescription Drug User Fee Act (PDUFA) date of January 16, 2010. Operating expenses for the third quarter declined 38% to $42.8 million, primarily due to a huge reduction in R&D expenses. Reduced costs associated with the clinical development of Afresa along with a decline in manufacturing costs brought down ...

Amgen Beats, Raises Guidance – Analyst Blog

Zacks Market Commentaries (October 22nd, 2009) Writes:
  Amgen (AMGN) reported third quarter earnings per share of $1.47, well above the Zacks Consensus Estimate of $1.26 and 21% above the year-ago earnings of $1.21. Cost cuts and a lower tax rate helped boost the top-line despite a 2% decline in total revenues, which came in at $3,812 million. Total product sales decreased 1% to $3,736 million. While sales in the U.S. were relatively unchanged at $2,918 million, international sales declined 4% to $818 million mainly due to the unfavorable impact of foreign exchange (Fx) fluctuation, which affected sales by approximately $76 million. Aranesp sales declined 19% to $685 million (U.S. - $333 million, down 27%; ex-U.S. - $352 million, down 9%), mainly due to a decline in demand reflecting the negative impact, primarily in the supportive cancer care setting, of additional product label changes which occurred in August 2008. Aranesp continued to lose share ...

Dendreon to Seek FDA Approval – Analyst Blog

Zacks Market Commentaries (October 9th, 2009) Writes:
Recently, Dendreon Corp. (DNDN) announced that it intends to file an amendment to its existing Biologic License Application (BLA) for its prostate cancer vaccine Provenge in Nov. 2009. We believe that the US Food and Drug Administration (FDA) will approve Provenge in the first half of 2010 based on the positive phase III IMPACT (IMmunotherapy for Prostrate AdenoCarcinoma Treatment) trial results announced in Apr. 2009.   If approved, Dendreon will become the first company to receive approval for an anti-cancer immunotherapy based vaccine. In development studies, Provenge boosted survival rates in men with advanced prostate cancer beyond any currently available treatments. Unlike traditional vaccines that prevent diseases, Provenge treats it by stimulating the body's own immune system to attack cancer cells. We also expect the company to announce a partner for Provenge in Europe soon while Dendreon itself will market the drug in the U.S.   Prostate cancer ...

COV, PWRM, MSFT, CSRH, NKE, CVAT, ABT, DrStockPick.com Stock Report!

Dr. Stock Pick (September 30th, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_________________________________________

drstock-2-3

FREE Daily Stock Alerts From DrStockPick.com

signup3m

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

COV, PWRM, MSFT, CSRH, NKE, CVAT, ABT

**************************************************************

COV, Covidien plc

COV engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings worldwide. The company operates through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products, and Medical Supplies.

COV said Wednesday it received Food and Drug Administration clearance for its new endotracheal tube, a device that helps patients breathe.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the

...
Tags for this Post:
Abbott Laboratories, ABT, accessory products, adult and pediatric pharmaceuticals, advertisement services, advertising services, ALS, anemia, anesthesia products, ankylosing spondylitis;, anti-infectives, apparel, Asia, Baseball, basketball, Beijing, beverage, bipolar disorder, Breast Cancer, broker, cancer, Cavitation Technologies Inc., ceo, Chair and Keynote Speaker, Charles Mandeville, chemical industries, Chemist, chief scientific officer, China, Congress, Consorteum Holdings Inc.;, Covidien plc, credit card transaction processing, Crown Equity Holdings Inc.;, CSRH, diagnostic tests, Dr Stock Pick, dyslipidemia;, Electricity, electronic transaction processing;, endometriosis, Energy Costs, epilepsy, equipment, equity trader, Federal judge, Financial Services, food, Food And Drug Administration, football, Footwear, golf, hardware products;, health care products, healthcare, healthcare products, HIV infection, Houston, hypothyroidism, International Congress, Investing Lessons, Ira Goldknopf, leader in the development, Media Center, Microsoft Corporation, migraines;, Moberly, neurodegenerative disease;, Nike Inc, North America, obesity, outdated technologies, payment processing industry, Power 3 Medical Products Inc., Power3 Medical Products Inc.;, Power3;, precocious puberty, president, President & COO, producer, professional investment analyst and consultant, Prostate Cancer, psoriasis, psoriatic arthritis;, Quent Rickerby;, Rheumatoid Arthritis, Rhode Island, Roman Gordon, secondary hyperparathyroidism, skateboarding, soccer, South America, SRS Engineering Inc., stock featured on our site;, Stock Pick, Stocks to Watch, systems, systems technologies, technology solutions, tennis, Texas, transaction processing industries;, transactional processing systems;, USD, uterine fibroids;, vegetable oil refining, volleyball, wall street, Windows Vista, Windows XP, wrestling, www.consorteum.com, www.crowntradingsystems.com, www.crwenews.com, www.drstockpick.com, www.pcsoyenergy.com, www.power3medical.com, www.processconcepts.com, www.srsengineering.com, www.stock-ir.com

Dendreon Awaits Provenge Approval – Analyst Blog

Zacks Market Commentaries (September 28th, 2009) Writes:
Dendreon Corporation (DNDN) is likely to become the first company to receive approval from the US Food and Drug  Administration (FDA) for an anti-cancer, immunotherapy based vaccine, as it released phase III IMPACT (IMmunotherapy for Prostrate AdenoCarcinoma Treatment) trial results for its key product candidate, Provenge, in April 2009. Provenge boosted survival rates in men with advanced prostate cancer beyond any currently available treatments. Dendreon intends to file an amendment to its existing Biologic License Application (BLA) in the fourth quarter of 2009. We believe that the FDA will approve Provenge in the first half of 2010 based on the positive late-stage study results. We also expect the company to announce a partner for Provenge in Europe soon while Dendreon itself will market the drug in the U.S. We believe Provenge could have blockbuster potential if it is approved by the regulators. Prostate cancer is the most ...

XRX, PWRM, ABT, CSRH, CMCSA, CVAT, FMCN, DrStockPick.com Stock Report!

Dr. Stock Pick (September 28th, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_________________________________________

drstock-2-3

FREE Daily Stock Alerts From DrStockPick.com

signup3m

_________________________________________

Monday September 28, 2009

DrStockPick.com Stock Report!

XRX, PWRM, ABT, CSRH, CMCSA, CVAT, FMCN

**************************************************************

XRX, Xerox Corp.

XRX engages in the development, manufacture, marketing, servicing, and financing of document equipment, software, solutions, and services worldwide.

XRX said Monday it will buy Affiliated Computer Services Inc. for $6.4 billion in cash and stock to create a $22 billion business that combines XRX’s copiers, printers and document management services with the “business process outsourcing” of Dallas-based ACS., joining the expensive race among technology companies to broaden their offerings.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in

...
Tags for this Post:
Abbott Laboratories, ABT, adult and pediatric pharmaceuticals, advertisement services, advertising services, Affiliated Computer Services Inc., ALS, anemia, anesthesia products, ankylosing spondylitis;, anti-infectives, Argentina, Beijing, beverage, bipolar disorder, Breast Cancer, broker, cable services;, cancer, Cavitation Technologies Inc., ceo, Chair and Keynote Speaker, chemical industries, chemicals maker;, chief scientific officer, China, Chinese Ministry of Commerce, Comcast Corporation;, communication products, communications products, Congress, Consorteum Holdings Inc.;, credit card transaction processing, Crown Equity Holdings Inc.;, CSRH, Cupertino;, Dallas, diagnostic tests, digital media, digital out-of-home advertising networks, document equipment, document management services, Dow Chemical, Dr Stock Pick, dyslipidemia;, electronic transaction processing;, endometriosis, epilepsy, equity trader, Fda, Financial Services, Focus Media Holding Ltd., food, health care products, healthcare, HIV infection, Houston, hypothyroidism, International Congress, Investing Lessons, Ira Goldknopf, Latin America, leader in the development, Los Altos, migraines;, Milpitas, mobile handset advertising, Mountain View, neurodegenerative disease;, North America, obesity, out-of-home advertising network, outdated technologies, Palo Alto;, payment processing industry, Pharmaceutical, Power 3 Medical Products Inc., Power3 Medical Products Inc.;, Power3;, precocious puberty, president, President & COO, professional investment analyst and consultant, Prostate Cancer, psoriasis, psoriatic arthritis;, Quent Rickerby;, Rheumatoid Arthritis, Ricoh XR-X 3PF Film Camera;, Roman Gordon, San Francisco, San Rafael, Santa Clara, Saratoga, secondary hyperparathyroidism, SINA Corporation;, Solvay, stock featured on our site;, Stock Pick, Stocks to Watch, Sunnyvale, Technology, technology solutions, Texas, transaction processing industries;, transactional processing systems;, United States, USD, uterine fibroids;, Vacaville, vegetable oil refining, www.alsbio.com, www.consorteum.com, www.crowntradingsystems.com, www.crwenews.com, www.dow.com, www.drstockpick.com, www.power3medical.com, www.stock-ir.com, Xerox Corp.;, XRX

Favorable Data from Incyte – Analyst Blog

Zacks Market Commentaries (September 24th, 2009) Writes:
Recently, Incyte Corporation (INCY) presented impressive data from a mid-stage trial for its pipeline candidate INCB18424 for psoriasis treatment. The phase IIb trial, carried out on 200 patients over a period of three months, compared three once-daily doses of the drug compared to the placebo. It was observed that patients treated with INCB18424 had a statistically significant improvement over the placebo in reducing total lesion score (erythema + scaling + thickness), which was also the primary endpoint of the trial. In addition, the trial met its secondary endpoint which was the Physician Global Assessment score and the Psoriasis Area and Severity Index score. Apart from psoriasis, Incyte is conducting trials of INCB18424 for several other indications which include myelofibrosis, polycythemia vera/essential thrombocythemia, rheumatoid arthritis, refractory prostate cancer and multiple myeloma. Incyte has other potential candidates targeting treatment for diabetes, breast cancer and HIV. However, the ...

Good News for Amgen’s Pipeline – Analyst Blog

Zacks Market Commentaries (September 22nd, 2009) Writes:
Amgen (AMGN) maintained a strong presence at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany where the company presented data on lead pipeline candidate, denosumab. The company presented solid data on denosumab from a phase III study that was conducted in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. Top-line results from this study were presented in August 2009. Overall results were good, with denosumab not causing any imbalance in overall survival (OS) or disease progression. Results showed that the median time to first on-study skeletal-related event (SRE) was 20.6 months for patients receiving denosumab and 16.3 months for patients receiving Novartis’ (NVS) Zometa. These results are statistically significant for non-inferiority. Denosumab also delayed the median time to first on-study SRE or hypercalcemia of malignancy (HCM) compared to Zometa. ...

PWRM, AMGN, DrStockPick.com Stock Report! Power 3 Medical Products Inc, PWRM.OB and Amgen Inc.

Dr. Stock Pick (September 16th, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_______________________________________

drstock-2-3

FREE Daily Stock Alerts From DrStockPick.com

signup3m

_______________________________________

Wednesday September 16, 2009

DrStockPick.com Stock Report!

PWRM, Power 3 Medical Products Inc, PWRM.OB

AMGN, Amgen Inc.

**************************************************************

Power3 Medical Products, Inc. Headlines Session at International Molecular Diagnostic Meeting in China

- Power3 Medical Products, Inc. a Leader in Neurodegenerative Disease and Cancer Diagnostic Biomarkers Announces its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009 -

Power3 Medical Products, Inc. (OTC BB: PWRM), is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development

...
Tags for this Post:
ALS, American Academy of Neurology, Amgen Inc., Beijing, Berlin, Breast Cancer, broker, cancer, ceo, Chair and Keynote Speaker, Chemotherapy, chief scientific officer, China, colorectal cancer, Congress, Crown Equity Holdings Inc.;, diagnostic tests, Dr Stock Pick, equity trader, Executive Vice President, Executive Vice President of Research and Development, Fda, Germany, Houston, International Congress, Ira Goldknopf, Keynote Speaker, leader, metastases, multiple myeloma, neurodegenerative disease;, neurodegenerative diseases, Park;, Power 3 Medical Products Inc., Power3 Medical Products Inc.;, Power3;, president, professional investment analyst and consultant, Prostate Cancer, Reuters, Roger M. Perlmutter, Seattle, stock featured on our site;, Stock Pick, Stocks to Watch, Texas, treatment of bone metastases in advanced cancer, treatment of metastatic colorectal cancer, tumors, Vectibix® (panitumumab), Vice President of Research and Development, Vienna, www.BestOTC.com, www.crowntradingsystems.com, www.crwenews.com, www.drstockpick.com, www.PennyOmega.com, www.stock-ir.com, www.stock-pr.com, Zometa® (zoledronic acid)

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.